Fidaxomicin (Dificid), a novel oral macrocyclic antibacterial agent for the treatment of clostridium difficile-associated diarrhea in adults

P and T

Volumn 37, Issue 5, 2012, Pages 278-281

  Cruz, Martin Paspe ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BICARBONATE; CYCLOSPORIN; DRUG METABOLITE; FIDAXOMICIN; GLYCOPROTEIN P; LIVER ENZYME; METRONIDAZOLE; OP 1118; PLACEBO; RIFAMPICIN; RIFAXIMIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ABDOMINAL TENDERNESS; AGING; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BICARBONATE BLOOD LEVEL; BREAST FEEDING; CLOSTRIDIUM DIFFICILE INFECTION; COMORBIDITY; DIET RESTRICTION; DISINFECTION; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG INDICATION; DRUG INFORMATION; DRUG LABELING; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DYSPEPSIA; DYSPHAGIA; FLATULENCE; GASTROINTESTINAL HEMORRHAGE; HAND WASHING; HEALTH EDUCATION; HUMAN; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INFECTION RISK; INTESTINE OBSTRUCTION; LENGTH OF STAY; MAXIMUM PLASMA CONCENTRATION; MEGACOLON; METABOLIC ACIDOSIS; MINIMUM INHIBITORY CONCENTRATION; NASOGASTRIC TUBE; NAUSEA; NEUTROPENIA; NURSING HOME PATIENT; PATIENT CARE; PREGNANT WOMAN; PREVENTION AND CONTROL; PROTEIN EXPRESSION; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECOMMENDED DRUG DOSE; RECURRENCE RISK; RISK ASSESSMENT; SIDE EFFECT; SURGICAL TECHNIQUE; THROMBOCYTE COUNT; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; VOMITING;

EID: 84863658958     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Drekonja DM, Butler M, MacDonald R, et al. Comparative effectiveness of Clostridium difficile treatments: A systematic review. Ann Intern Med 2011;155: 839-847.
2. Gerding DDN, Johnson S, Peterson LR, et al. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 1995;16:459-477.
3. Reinke CM, Messick CR. Update on Clostridium difficile-induced colitis (parts 1 and 2). Am J Hosp Pharm 1994;51:1771-1781, 1892-1901.
4. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. Am J Gastroenterol 1997;92:739-750.
5. American Society of Health-System Pharmacists. Pharmacy News. Fidaxomicin approved for C. difficile infections, May 31, 2011. Available at: www.ashp.org/menu/News/PharmacyNews/NewsArticle.aspx?id=3549. Accessed February 29, 2012.
6. Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002;34:346-353.
7. Schroeder MS. Clostridium difficile- associated diarrhea. Am Fam Physician 2005;71:921-928.
8. Dallal RM, Harbrecht BG, Boujoukas AJ, et al. Fulminant Clostridium difficile: An underappreciated and increasing cause of death and complications. Ann Surg 2002; 235:363-372.
9. Bartlett JG. Clinical practice: Antibioticassociated diarrhea. N Engl J Med 2002; 346:334-339.
10. Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difficile-related mortality rates: United States, 1999-2004. Emerg Infect Dis 2007;13:1417-1419.
11. Wenisch C, Parschalk B, Hasenhündl M, et al. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996; 22:813-818.
12. Teasley DG, Gerding DN, Olson MM, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhoea and colitis. Lancet 1983;2:1043-1046.
13. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America 421 (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010;31(5):431-455.
14. Hospital Infection Control Practices Advisory Committee (HICPAC). Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 1995;16:105-113.
15. Olson MM, Shanholtzer CJ, Lee JT Jr, Gerding DN. Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991. Infect Control Hosp Epidemiol 1994;15: 371-381.
16. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011;364:422-431.
17. Dificid (fidaxomicin) Tablets, prescribing information. San Diego, Calif.: Optimer Pharmaceuticals; May 2011. Available at: www.dificid.com/files/ prescribing.pdf. Accessed March 15, 2012.
18. Ackermann G, Loffler B, Adler D, Rodloff AC. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother 2004;48:2280-2282.
19. Thomson Reuters Drugdex. Fidaxomicin. Available at: www.thomsonhc.com. Accessed February 29, 2012.